LOX-1 and atherosclerosis: proof of concept in LOX-1-knockout mice.
Morawietz
Henning
H
D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology; D001011:Aorta / Q000378:metabolism; D050197:Atherosclerosis / Q000097:blood / Q000235:genetics* / Q000378:metabolism; D002791:Cholesterol, Dietary; D004195:Disease Models, Animal; D018450:Disease Progression; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology; D008077:Lipoproteins, LDL / Q000097:blood / Q000378:metabolism; D051379:Mice; D018345:Mice, Knockout; D017382:Reactive Oxygen Species / Q000378:metabolism; D011973:Receptors, LDL / Q000235:genetics; D051127:Scavenger Receptors, Class E / Q000235:genetics* / Q000378:metabolism
D000959:Antihypertensive Agents; D002791:Cholesterol, Dietary; D000960:Hypolipidemic Agents; D008077:Lipoproteins, LDL; C495138:Olr1 protein, mouse; D017382:Reactive Oxygen Species; D011973:Receptors, LDL; D051127:Scavenger Receptors, Class E